Lancet: The clinical success of Rusolitini's treatment of vitiligo phase II

!---- vitiligo is a chronic autoimmune disease that causes the patient's skin pigment loss and the quality of life to decreasecurrently effective glyceme therapy, researchers recently examined the therapeutic potential of Rusolitini cream for patients with vitiligoresearchers and personnel recruited adult patients with vitiligo in 26 hospitals and medical centers in the United States to conduct a multi-center, random, double-blind, phase II study0.5% or more of the facial surface area (BSA) and 3% or more non-facial BSA decolorization patients received Rusolitini cream (content 1.5% twice daily, content 1.5% daily, content 0.5% daily, content 0.15% daily) or placebo, 2 times a day, each treatment accounted for 20% or less of the total BSA, for 24 weekspatients with a daily group of 0.15 percent, patients with a 25 percent or higher improvement in the facial vitiligo area scoring index (F-VASI) at the 24th week were regrouped into higher doses of Rusolitini cream (0.5 percent daily, 1.5 percent daily, 1.5 percent twice daily) until the 52nd weekThe main endpoint of thestudy was the proportion of patients with a 50 percent or higher percentage of F-VASI (F-VASI50) at the 24th week than the baseline in the intended treatment population157 patients (average age, 48.3 years, 73 men and 84 women) participated in the study, of which 32 (20%) were in the control group and 31 (20%) were 0.1 5% of the daily group, 31 cases (20%) for 0.5% daily group, 30 cases (19%) for 1.5% of the daily group, 33 cases (21%) for 1.5% of the daily grouppatients who used 1.5% of Russolitini cream twice daily (15/33) and 1.5% daily (15/30), and significantly higher than those who reached F-VASI50 at week 24 (1/32)4 patients had severe adverse events (1 case of sub-epidural hematoma in 1.5% of the daily group; 1 seizure in 1.5% daily group; 1 case of coronary artery closure in 0.5% daily group; and 1 case of esophageal hysdoncya in 0.5% daily group), but were not related to the studythe most common adverse events in theRusolitinib group were itching (1 in 33 cases in 1.5% of the 2 daily groups; 3 cases in 30 cases in 1.5% daily group; 3 cases in 31 cases in 0.5% daily group; and 6 cases in 31 cases in 0.15% daily group), of which 3 cases of drug itching occurred in 32 cases in the control group13 (10%) of 125 patients receiving Rusolitenini cream and 1 (3%) of 32 patients receiving the control group cream developed acne, which was considered to be a treatment-related adverse eventall adverse events associated with treatment are mild or moderatestudies have found that Russolitini cream seislum can cause significant pigmentation and good tolerance for the skin loss site of vitiligo within 52 weeks